New drug combo aims to Re-Sensitize lung cancer to immunotherapy
NCT ID NCT07412262
First seen Feb 20, 2026 · Last updated Jun 19, 2026 · Updated 20 times
Summary
This phase 2 trial tests whether combining chidamide (a pill) with ivonescimab (an infusion) can help people with advanced non-small cell lung cancer whose tumors have stopped responding to immunotherapy. The study will enroll 32 adults with a specific protein marker (high YAP). Researchers will measure how long the cancer stays under control and how many tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
Guangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chidamide (tucidinostat) and ivonescimab (AK112)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer whose disease has stopped responding to immunotherapy.
What could go wrong
This is a small, early-phase trial with only 32 participants and no comparison group. The treatment may not work or could cause side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.